Svetlana G. Podlipaeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Svetlana G. Podlipaeva has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Ilya V. Zakharov
Institute of General Genetics of the Russian Academy of Sciences
3 shared publications - A Yur'EVna Shcherbina
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology Moscow Russia
2 shared publications - Darya V. Yukhacheva
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology Moscow Russia
2 shared publications - Dmitriy Sergeevich Abramov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
2 shared publications - Татьяна Сергеевна Шубина
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
2 shared publications - A. L. Khoreva
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
1 shared publication
Latest Publications
- 1 June 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2300590
Midline Low-Grade Gliomas of Early Childhood: Focus on Targeted Therapies
PURPOSE: Midline low-grade gliomas (mLGGs) of early childhood have a poorer prognosis compared with tumors of other localizations and in older patients. LGGs are associated with aberrant activation of RAS-RAF-MEK pathway, and pharmacological inhibition of the pathway has therapeutic promise. The aim of this study was clinical and molecular characterization of infantile mLGGs, with emphasis on the efficacy of targeted kinase inhibition. PATIENTS AND METHODS: This study enrolled 40 patients with mLGG age <3 years. The majority of the patients (30/40) received first-line chemotherapy (CT) as per International Society of Paediatric Oncology LGG 2004 guidelines. In all patients, molecular genetic investigation of tumor tissue by polymerase chain reaction and RNA sequencing was performed. The median follow-up was 3.5 years. RESULTS: First-line CT failed in 24 of 30 recipients. The identified molecular profiles included KIAA1549::BRAF fusions in 26 patients, BRAF V600E in six patients, FGFR1::TACC1 fusions in two patients, and rare fusion transcripts in four patients. At disease progression, targeted therapy (TT) was initiated in 27 patients (22 patients received trametinib) on the basis of molecular findings. TT was administered for a median of 16 months, with partial response achieved in 12 of 26 (46%) patients in which response was evaluated. Severe adverse events were detected only on trametinib monotherapy: acute damage of GI or urinary mucosa complicated by hemorrhage and development of transfusion-dependent anemia in four patients and grade 3 skin toxicity in three patients. CONCLUSION: mLGGs of early childhood are often aggressive tumors, resistant to CT, and frequently require alternative treatment. The majority of patients harbor druggable molecular targets and respond to molecular TT.
- 1 June 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2300590
Midline Low-Grade Gliomas of Early Childhood: Focus on Targeted Therapies
PURPOSE: Midline low-grade gliomas (mLGGs) of early childhood have a poorer prognosis compared with tumors of other localizations and in older patients. LGGs are associated with aberrant activation of RAS-RAF-MEK pathway, and pharmacological inhibition of the pathway has therapeutic promise. The aim of this study was clinical and molecular characterization of infantile mLGGs, with emphasis on the efficacy of targeted kinase inhibition. PATIENTS AND METHODS: This study enrolled 40 patients with mLGG age <3 years. The majority of the patients (30/40) received first-line chemotherapy (CT) as per International Society of Paediatric Oncology LGG 2004 guidelines. In all patients, molecular genetic investigation of tumor tissue by polymerase chain reaction and RNA sequencing was performed. The median follow-up was 3.5 years. RESULTS: First-line CT failed in 24 of 30 recipients. The identified molecular profiles included KIAA1549::BRAF fusions in 26 patients, BRAF V600E in six patients, FGFR1::TACC1 fusions in two patients, and rare fusion transcripts in four patients. At disease progression, targeted therapy (TT) was initiated in 27 patients (22 patients received trametinib) on the basis of molecular findings. TT was administered for a median of 16 months, with partial response achieved in 12 of 26 (46%) patients in which response was evaluated. Severe adverse events were detected only on trametinib monotherapy: acute damage of GI or urinary mucosa complicated by hemorrhage and development of transfusion-dependent anemia in four patients and grade 3 skin toxicity in three patients. CONCLUSION: mLGGs of early childhood are often aggressive tumors, resistant to CT, and frequently require alternative treatment. The majority of patients harbor druggable molecular targets and respond to molecular TT.
- Open Access
- 22 December 2021
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 20 (4) , 48-53
The role of endoscopy in the diagnosis of acute intestinal “graft-versus-host” disease after allogeneic hematopoietic stem cell transplantation
Hematopoietic stem cell transplantation (HSCT) is an effective method of therapy which is widely used for the treatment of a number of diseases in children. “Graft-versus-host” disease (GVHD) is a severe complication that can develop after HSCT. The incidence of GVHD, according to some authors, ranges from 40 to 60%. The main target organs of acute GVHD are skin, liver, and gastrointestinal tract. Early diagnosis is critical in choosing the optimal treatment. The clinical manifestations of intestinal GVHD are non-specific. Currently, the “gold standard” of GVHD diagnosis is the histopathological assessment of biopsy samples. However, a conditioning regimen, cytomegalovirus infection, and/or treatment with immunosuppressive drugs can also induce apoptosis and lead to the same microscopic changes as the ones seen in GVHD. The main goals of an endoscopic examination are the visual assessment of the mucosa and a biopsy. Several articles describe macroscopic changes in the colonic mucosa characteristic of GVHD which can be used as a diagnostic criterion. Here, we review related literature and report a case of severe acute GVHD as well as evaluate the patient’s clinical manifestations and endoscopic findings. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.
- 22 December 2021
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 20 (4) , 48-53
Open AccessThe role of endoscopy in the diagnosis of acute intestinal “graft-versus-host” disease after allogeneic hematopoietic stem cell transplantation
Hematopoietic stem cell transplantation (HSCT) is an effective method of therapy which is widely used for the treatment of a number of diseases in children. “Graft-versus-host” disease (GVHD) is a severe complication that can develop after HSCT. The incidence of GVHD, according to some authors, ranges from 40 to 60%. The main target organs of acute GVHD are skin, liver, and gastrointestinal tract. Early diagnosis is critical in choosing the optimal treatment. The clinical manifestations of intestinal GVHD are non-specific. Currently, the “gold standard” of GVHD diagnosis is the histopathological assessment of biopsy samples. However, a conditioning regimen, cytomegalovirus infection, and/or treatment with immunosuppressive drugs can also induce apoptosis and lead to the same microscopic changes as the ones seen in GVHD. The main goals of an endoscopic examination are the visual assessment of the mucosa and a biopsy. Several articles describe macroscopic changes in the colonic mucosa characteristic of GVHD which can be used as a diagnostic criterion. Here, we review related literature and report a case of severe acute GVHD as well as evaluate the patient’s clinical manifestations and endoscopic findings. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.
- Open Access
- 21 December 2021
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 20 (4) , 108-115
Clinical variants of esophageal stenosis caused by infectious esophagitis in children
Infectious esophagitis (IE) is commonly seen in immunocompromised patients. IE may be the first symptom of immunodeficiency state, also can be complication of immunosuppressive therapy in patients with hematological and oncological diseases. Severe complication of IE is esophageal stenosis. Patient management tactics continue to be discussed. A purpose of our publication is to demonstrate our experience in the management of patients with infectious esophageal stenosis. The etiology, features of the clinical and endoscopic picture, as well as the effectiveness of drug therapy and endoscopic methods of treatment have been analyzed. The study was approved by the Independent Ethics Committee and the Scientific Council of the D. Rogachev NMRCPHOI. In each case, parents gave their consent to the use of their child’s data, including photographs, for research purposes and in publications.
- 21 December 2021
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 20 (4) , 108-115
Open AccessClinical variants of esophageal stenosis caused by infectious esophagitis in children
Infectious esophagitis (IE) is commonly seen in immunocompromised patients. IE may be the first symptom of immunodeficiency state, also can be complication of immunosuppressive therapy in patients with hematological and oncological diseases. Severe complication of IE is esophageal stenosis. Patient management tactics continue to be discussed. A purpose of our publication is to demonstrate our experience in the management of patients with infectious esophageal stenosis. The etiology, features of the clinical and endoscopic picture, as well as the effectiveness of drug therapy and endoscopic methods of treatment have been analyzed. The study was approved by the Independent Ethics Committee and the Scientific Council of the D. Rogachev NMRCPHOI. In each case, parents gave their consent to the use of their child’s data, including photographs, for research purposes and in publications.
- Open Access
- 11 January 2021
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 19 (4) , 50-61
Non-infectious complications in the group of pediatric patients with chronic granulomatous disease
Характеристика неинфекционных проявлений хронической гранулематозной болезни в группе педиатрических пациентов
- 11 January 2021
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 19 (4) , 50-61
Open AccessNon-infectious complications in the group of pediatric patients with chronic granulomatous disease
Характеристика неинфекционных проявлений хронической гранулематозной болезни в группе педиатрических пациентов
- 9 February 2018
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 17 (1) , 60-63
Endoscopy for children with thrombocytopenia: Single center experience
Oncological, hematological and immunological diseases themselves or in the course of treatment are often accompanied by a decrease in the parameters of peripheral blood. If there are indications for endoscopy, the doctor performing the research should necessarily evaluate the safety of the procedure and the risks of bleeding in thrombocytopenia. To date, there are no single hematological criteria in the world for safe endoscopy procedure. The aim of the work is to evaluate the possibility of carrying out endoscopic studies in patients with thrombocytopenia and to determine the indications for blood transfusion therapy. The retrospective analysis included 82 patients aged 2 months to 18 years (median age – 9.6 years), who were treated at the Dmitry Rogachev National Center from January 2016 to March 2017, and who underwent diagnostic endoscopy with a platelet count ≤ 50×109/l or an endopic study with biopsy at a platelet count of ≤ 80×109/l, and 19 patients aged 1–18 years (median – 9.26 years), whom endoscopy was performed with prophylactic platelets transfusion. In the endoscopic examination, contact bleeding was observed in 17% of patients who did not receive prophylactic transfusion of platelets and in 21% of patients who underwent transfusion of platelet suspension prior to the study. When carrying out the diagnostic procedure (bronchoscopy and gastroscopy) with a platelet count of more than 20×109/l (median – 34×109/l), no spontaneous bleeding was observed, as well as minimal hemorrhagic syndrome. A safe endoscopy examination is possible to perform even in patients with thrombocytopenia, but clearly defined indications.
- 9 February 2018
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 17 (1) , 60-63
Endoscopy for children with thrombocytopenia: Single center experience
Oncological, hematological and immunological diseases themselves or in the course of treatment are often accompanied by a decrease in the parameters of peripheral blood. If there are indications for endoscopy, the doctor performing the research should necessarily evaluate the safety of the procedure and the risks of bleeding in thrombocytopenia. To date, there are no single hematological criteria in the world for safe endoscopy procedure. The aim of the work is to evaluate the possibility of carrying out endoscopic studies in patients with thrombocytopenia and to determine the indications for blood transfusion therapy. The retrospective analysis included 82 patients aged 2 months to 18 years (median age – 9.6 years), who were treated at the Dmitry Rogachev National Center from January 2016 to March 2017, and who underwent diagnostic endoscopy with a platelet count ≤ 50×109/l or an endopic study with biopsy at a platelet count of ≤ 80×109/l, and 19 patients aged 1–18 years (median – 9.26 years), whom endoscopy was performed with prophylactic platelets transfusion. In the endoscopic examination, contact bleeding was observed in 17% of patients who did not receive prophylactic transfusion of platelets and in 21% of patients who underwent transfusion of platelet suspension prior to the study. When carrying out the diagnostic procedure (bronchoscopy and gastroscopy) with a platelet count of more than 20×109/l (median – 34×109/l), no spontaneous bleeding was observed, as well as minimal hemorrhagic syndrome. A safe endoscopy examination is possible to perform even in patients with thrombocytopenia, but clearly defined indications.